- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:06 | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations | 202 | GlobeNewswire (Europe) | NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia... ► Artikel lesen | |
| 22.06. | LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright | 2 | Investing.com | ||
| 09.06. | LB PHARMACEUTICALS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | LB Pharmaceuticals Inc: LB Pharmaceuticals to Participate in Upcoming June Investor Events | 1 | GlobeNewswire (USA) | ||
| LB PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 26.05. | Clear Street stuft LB Pharmaceuticals mit "Buy" ein und sieht Blockbuster-Potenzial | 1 | Investing.com Deutsch | ||
| 26.05. | Clear Street initiates LB Pharmaceuticals stock with buy rating | 1 | Investing.com | ||
| 26.05. | H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target | 1 | Investing.com | ||
| 26.05. | H.C. Wainwright bestätigt Kaufempfehlung für LB Pharmaceuticals mit Kursziel von 45 US-Dollar | - | Investing.com Deutsch | ||
| 12.05. | LB PHARMACEUTICALS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | LB PHARMACEUTICALS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | 188 | GlobeNewswire (Europe) | Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1... ► Artikel lesen | |
| 27.04. | This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | 1 | Benzinga.com | ||
| 22.04. | LB Pharmaceuticals: Aktie nach positiven Studiendaten zu Schizophrenie-Mittel auf Höhenflug | 1 | Investing.com Deutsch | ||
| 22.04. | LB Pharmaceuticals publishes phase 2 schizophrenia trial results | 1 | Investing.com | ||
| 22.04. | LB Pharmaceuticals Inc: LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia | 1 | GlobeNewswire (USA) | ||
| 10.04. | Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating | 3 | Investing.com | ||
| 06.04. | LB PHARMACEUTICALS INC - S-1, General form for registration of securities | - | SEC Filings | ||
| 27.03. | LB Pharmaceuticals presents LB-102 cognitive data at SIRS meeting | 2 | Investing.com | ||
| 27.03. | LB Pharmaceuticals legt positive kognitive Daten für Schizophrenie-Wirkstoff LB-102 vor | 1 | Investing.com Deutsch | ||
| 27.03. | LB Pharmaceuticals Inc: LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society ... | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,560 | +7,59 % | BRANDMELDUNG bei InnoCan Pharma: Könnte die Aktie jetzt komplett durchstarten? - Was Sie jetzt noch wissen müssen | ||
| JAGUAR HEALTH | 3,000 | +1,35 % | Jaguar Health, Inc.: Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure | Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseasesNear-term milestones for IF program buttressed by continuing groundbreaking results of study... ► Artikel lesen | |
| KALA BIO | 1,755 | -16,03 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,700 | -2,12 % | Ironwood Pharmaceuticals, Inc.: Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance | Expects full-year 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million -
Ended Q4 2025 with greater than... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 4,040 | -7,34 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,280 | -0,87 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 14,300 | -1,11 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| MINDWALK | 1,350 | -6,90 % | Highflyer der Zukunft - "Must Have" für ihr Biotech-Depot?! | ||
| KIORA PHARMACEUTICALS | 2,600 | -0,38 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model | Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator... ► Artikel lesen | |
| LIPOCINE | 2,490 | 0,00 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,310 | -4,38 % | InMed Pharmaceuticals: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements | Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,370 | -3,80 % | HERON THERAPEUTICS, INC. /DE/ - 8-K, Current Report | ||
| HARROW | 36,800 | +0,55 % | Harrow, Inc.: Harrow Health, Inc. Re-Launches VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare | VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriersVERKAZIA... ► Artikel lesen | |
| INVENTIVA | 3,200 | +1,75 % | Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside | ||
| MEDICINOVA | 1,330 | +1,53 % | MediciNova completes patient visits in phase 2 NAFLD trial |
LB PHARMACEUTICALS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,360 (+1,10 %) liegt der Kurs bei 33,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LB PHARMACEUTICALS INC finden Sie auf Wallstreet Online.